This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Freeline Therapeutics Holdings Beheer

Beheer criteriumcontroles 2/4

De CEO Freeline Therapeutics Holdings is Michael Parini, benoemd in Aug2021, heeft een ambtstermijn van 2.5 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 2.16M, bestaande uit 27.4% salaris en 72.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.1% van de aandelen van het bedrijf, ter waarde $ 310.01K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.1 jaar en 4.3 jaar.

Belangrijke informatie

Michael Parini

Algemeen directeur

US$2.2m

Totale compensatie

Percentage CEO-salaris	27.4%
Dienstverband CEO	2.5yrs
Eigendom CEO	1.1%
Management gemiddelde ambtstermijn	2.1yrs
Gemiddelde ambtstermijn bestuur	4.3yrs

Recente managementupdates

Recent updates

Calculating The Intrinsic Value Of Freeline Therapeutics Holdings plc (NASDAQ:FRLN)

Jul 13

Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely

Apr 11

Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely

Dec 20

We're Keeping An Eye On Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Rate

Aug 30

Freeline gains as NEJM publishes long-term data for hemophilia therapy

Jul 21

Is Freeline Therapeutics Holdings (NASDAQ:FRLN) In A Good Position To Invest In Growth?

May 05

Will Freeline Therapeutics Holdings (NASDAQ:FRLN) Spend Its Cash Wisely?

Jan 13

Companies Like Freeline Therapeutics Holdings (NASDAQ:FRLN) Could Be Quite Risky

Sep 30

Here's Why We're Watching Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Situation

Jun 03

What Kind Of Shareholders Hold The Majority In Freeline Therapeutics Holdings plc's (NASDAQ:FRLN) Shares?

Feb 18

Analyse CEO-vergoeding

Hoe is Michael Parini's beloning veranderd ten opzichte van Freeline Therapeutics Holdings's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2023	n/a	n/a	-US$50m
Jun 30 2023	n/a	n/a	-US$53m
Mar 31 2023	n/a	n/a	-US$61m
Dec 31 2022	US$2m	US$591k	-US$89m
Sep 30 2022	n/a	n/a	-US$101m
Jun 30 2022	n/a	n/a	-US$117m
Mar 31 2022	n/a	n/a	-US$132m
Dec 31 2021	US$1m	US$419k	-US$140m

Compensatie versus markt: De totale vergoeding ($USD 2.16M ) Michael } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 651.15K ).

Compensatie versus inkomsten: De vergoeding van Michael is gestegen terwijl het bedrijf verliesgevend is.

CEO

Michael Parini (48 yo)

2.5yrs

Tenure

US$2,160,000

Compensatie

Mr. Michael J. Parini, JD., serves as Chief Executive Officer & Executive Director at Freeline Therapeutics Limited since August 16, 2021. He had been President and Chief Operating Officer at Freeline Ther...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Parini	CEO & Executive Director	2.5yrs	US$2.16m	1.1% $ 310.0k
Paul Schneider	CFO & Director	1.8yrs	geen gegevens	geen gegevens
Henning Stennicke	Chief Scientific Officer	1.9yrs	geen gegevens	geen gegevens
Nicole Jones	Chief People Officer	1.6yrs	geen gegevens	geen gegevens
James Bircher	Chief Technical Operations Officer	2.6yrs	geen gegevens	geen gegevens
Pamela Foulds	Chief Medical Officer	2.3yrs	geen gegevens	geen gegevens
Naomi Aoki	Senior Vice President of Corporate Communications & Investor Relations	no data	geen gegevens	geen gegevens
Amy Spandau	Interim Head of Finance	no data	geen gegevens	geen gegevens

2.1yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van FRLN wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.1 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Michael Parini	CEO & Executive Director	2.5yrs	US$2.16m	1.1% $ 310.0k
Paul Schneider	CFO & Director	less than a year	geen gegevens	geen gegevens
Julia Gregory	Independent Non-Executive Director	4.3yrs	US$172.00k	geen gegevens
Colin Love	Independent Non Executive Director	2.9yrs	US$93.00k	geen gegevens
Christopher Hollowood	Independent Chairman	8.2yrs	US$93.00k	geen gegevens
Jeffrey Chodakewitz	Independent Non-Executive Director	4.5yrs	US$166.00k	geen gegevens
Martin Andrews	Independent Non-Executive Director	5.3yrs	US$154.00k	geen gegevens

4.3yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van FRLN wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

This company has been acquired

Freeline Therapeutics Holdings Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Freeline Therapeutics Holdings plc, Annual General Meeting, Jun 28, 2023

Freeline Therapeutics Holdings plc, Annual General Meeting, Jun 28, 2022

Freeline Therapeutics Holdings plc Appoints Paul Schneider as Chief Financial Officer

Freeline Therapeutics Holdings plc Appoints Henning R. Stennicke as Chief Scientific Officer

High number of new directors

Freeline Therapeutics Holdings plc Announces the Appointment of Colin A. Love to its Board of Directors

Recent updates

Spur Therapeutics Completes Enrollment in Phase 1/2 Galileo-1 Trial of Flt201 in Gaucher Disease and Selects Dose for Planned Phase 3 Trial

Freeline Therapeutics Holdings plc acquired SwanBio Therapeutics, Inc. from Mass General Brigham Ventures, LLC, Syncona Investment Management Limited and Syncona Partners LLP.

Freeline Presents Positive New Data from Phase 1/2 Trial of FLT201, Its Novel Gene Therapy Candidate for Gaucher Disease, in Late-Breaking Oral Presentation at ASGCT 27th Annual Meeting

Freeline Therapeutics Files Form 15

Freeline Therapeutics Holdings plc(NasdaqCM:FRLN) dropped from NASDAQ Composite Index

Syncona Investment Management Limited completed the acquisition of the remaining 42.08% stake in Freeline Therapeutics Holdings plc (NasdaqCM:FRLN).

Freeline Therapeutics Holdings' ADSs to be No Longer Listed on Nasdaq After Completion of Acquisition by Newly Established Portfolio Company of Syncona

Freeline Therapeutics Holdings' ADSs to be No Longer Listed on Nasdaq After Completion of Acquisition by Newly Established Portfolio Company of Syncona

Freeline Therapeutics Holdings plc Presents Positive New Data from Phase 1/2 GALILEO-1 Trial of FLT201, Its Novel Gene Therapy Candidate

Consensus revenue estimates decrease by 93%

Syncona Investment Management Limited has submitted a non-binding proposal to acquire remaining 42.08% stake in Freeline Therapeutics Holdings plc (NasdaqCM:FRLN) for for $9.8 million.

Syncona Investment Management Limited has submitted a non-binding proposal to acquire remaining 42.08% stake in Freeline Therapeutics Holdings plc (NasdaqCM:FRLN) for approximately $140 million.

Freeline Therapeutics Holdings plc Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 Galileo-1 Trial of FLT201, Its Novel Gene Therapy Candidate, in Gaucher Disease

Price target increased by 12% to US$9.25

Consensus estimates of losses per share improve by 69%

Price target decreased by 24% to US$6.25

Now 21% undervalued after recent price drop

Calculating The Intrinsic Value Of Freeline Therapeutics Holdings plc (NASDAQ:FRLN)

New major risk - Share price stability

New major risk - Financial position

Freeline Therapeutics Holdings plc Announces First Patient Dosed with Its Novel Gene Therapy Candidate for Gaucher Disease and Unveils Research Program in GBA1-Linked Parkinson's Disease

Consensus revenue estimates decrease by 19%, EPS upgraded

Freeline Therapeutics Holdings plc, Annual General Meeting, Jun 28, 2023

Freeline Therapeutics Holdings Regains Compliance with the Nasdaq Minimum Bid Price Requirement

Freeline Therapeutics Holdings plc Receives ILAP Designation in United Kingdom by MHRA for FLT201, an Investigational Gene Therapy for the Treatment of Gaucher Disease

Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely

Freeline Therapeutics Holdings plc Announces the Publication of Preclinical Proof-Of-Concept Data for Its Gene Therapy Candidate for Fabry Disease, FLT190

Here's Why Freeline Therapeutics Holdings (NASDAQ:FRLN) Must Use Its Cash Wisely

Price target decreased to US$4.86

Freeline Initiates Dosing of Second Cohort in Marvel-1 Trial of Flt190 Gene Therapy Candidate for People with Fabry Disease

We're Keeping An Eye On Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Rate

Price target decreased to US$6.71

Price target decreased to US$7.43

Freeline gains as NEJM publishes long-term data for hemophilia therapy

Freeline Therapeutics Holdings plc Announces Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress

Freeline Therapeutics Holdings plc Announces Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress

Freeline to Present New Clinical Data for FLT180a in Hemophilia B at International Society on Thrombosis and Haemostasis Congress

Freeline Therapeutics Holdings plc Initiates Dosing of Second Cohort in B-LIEVE Dose Confirmation Trial of FLT180a in Hemophilia B

Freeline Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Freeline Therapeutics Holdings plc, Annual General Meeting, Jun 28, 2022

Is Freeline Therapeutics Holdings (NASDAQ:FRLN) In A Good Position To Invest In Growth?

Price target decreased to US$8.29

Freeline Therapeutics Holdings plc Appoints Paul Schneider as Chief Financial Officer

Price target decreased to US$9.33

Price target decreased to US$11.13

Freeline Therapeutics Holdings plc Appoints Henning R. Stennicke as Chief Scientific Officer

Will Freeline Therapeutics Holdings (NASDAQ:FRLN) Spend Its Cash Wisely?

Freeline Therapeutics Holdings plc Announces FDA Clearance of Investigational New Drug Application for FLT201 for Gaucher Disease Type 1

Price target decreased to US$12.00

Freeline Therapeutics Holdings plc Presents Long-Term Follow-Up Data from Phase 1/2 B-AMAZE Trial in Hemophilia B at the 2021 ASH Annual Meeting and Announces Early Initiation of Phase 1/2 B-LIEVE Dose-Confirmation Trial

Companies Like Freeline Therapeutics Holdings (NASDAQ:FRLN) Could Be Quite Risky

High number of new directors

Chief Scientific Officer Romuald Corbau has left the company

CEO & Director Theresa Heggie has left the company

Price target decreased to US$18.25

Chief Development Officer Jan Thirkettle has left the company

Freeline Doses Second Patient of Phase 1/2 Marvel-1 Clinical Trial for Fabry Disease

Here's Why We're Watching Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Situation

Freeline Therapeutics Holdings plc Presents Data Highlighting Platform Technology At the American Society of Gene and Cell Therapy Annual Meeting 2021

CFO & Head of Corporate Development has left the company

Freeline Therapeutics Holdings plc Announces the Appointment of Colin A. Love to its Board of Directors

New 90-day low: US$15.06

What Kind Of Shareholders Hold The Majority In Freeline Therapeutics Holdings plc's (NASDAQ:FRLN) Shares?

Freeline Therapeutics Holdings plc Announces Management Changes

Freeline Therapeutics Holdings plc Presents Data on Its Gaucher Disease and Fabry Disease AAV-Based Gene Therapies at the 17 Annual WORLDSymposium™

Freeline Therapeutics Updates Clinical Development Plan for its FLT180a Hemophilia B Program

New 90-day high: US$18.30

Freeline Reports Updated Data From Phase 1/2 B-AMAZE Trial in Hemophilia B